Emergent and GeoVax rise as mpox cases are reported outside Africa
16/08/2024 13:24
** Shares of mpox vaccine developers Emergent BioSolutions
EBS.N and GeoVax Labs GOVX.O rise premarket after cases of
mpox were found outside Africa
** A case of mpox is reported in Pakistan, while another was
reported in Sweden on Thursday
** WHO sounded its highest level of alert on Wednesday over
the outbreak in Africa after cases in the Democratic Republic of
Congo spread to nearby countries
** Premarket, shares of EBS rise 12.6% to $9.75, while
GOVX's shares up 9.9% at $3.53
** Brokerage Benchmark says EBS manufactures and supplies
ACAM2000 for prevention of smallpox, and earlier this year co
submitted US FDA application for its use in mpox, expecting
approval this quarter
** Brokerage Roth MKM sees GOVX's GEO-MVA vaccine, initially
developed for smallpox and later for mpox, to be its first
product to market
** Up to last close, EBS up over two-fold and GOVX down
38.1% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))